RxDoctor Payments Data

Simarjeet Manocha, PA

Physician Assistant · Lancaster, CANPI 1548725666

Payments from drug & device makers

$10,873in general payments, 2019–2025

Across 428 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AbbVie$931
  • Boehringer Ingelheim$676
  • Dexcom, Inc.$663
  • plus $4K from 50 others

What the payments were for

  • Travel & lodging$7107%
  • Food & beverage$10,13193%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,873 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$173,561
Medicare patients
412
Services billed
2,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide178$200,872
Synjardy XrEmpagliflozin/Metformin Hcl82$105,506
JardianceEmpagliflozin72$95,831
MounjaroTirzepatide57$67,416
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$64,438
RybelsusSemaglutide30$52,905
ProliaDenosumab26$43,913
FarxigaDapagliflozin Propanediol35$37,249
VascepaIcosapent Ethyl68$28,516
SynjardyEmpagliflozin/Metformin Hcl13$20,443
Tresiba Flextouch U-100Insulin Degludec22$13,675
LinzessLinaclotide16$11,301
MyrbetriqMirabegron16$10,587
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$10,244
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,419$253,777208 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$676$221,780167 claims
Lilly USA, LLCMounjaro$1,036$67,41657 claims
GSKTrelegy Ellipta$465$64,43892 claims
AmgenProlia$459$43,91326 claims
AstraZenecaFarxiga$282$37,24935 claims
AbbVieLinzess, Synthroid$931$13,93946 claims
Astellas Pharma US IncMyrbetriq$31$10,58716 claims
MerckBelsomra$282$5,07612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →